CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorZunyi Medical College
About this trial
In Ease Asia clinical trials, P2Y12 inhibitor (ticagrelor or clopidogrel) monotherapy after 3-month dual antiplatelet therapy (DAPT) resulted in a lower incidence of clinically significant bleeding, without increasing risk of major adverse cardiac and cerebrovascular events, even if acute coronary syndrome (ACS) following complex percutaneous coronary intervention (PCI) when compared with standard DAPT. Although better understood "East Asian Paradox", finding the right CYP2C19 genotype-guided P2Y12 inhibitor selection to balance maintaining ischaemic prevention and less bleeding remains a topic in real-world clinical practice.
Eligibility criteria
Qualifiers
Patients aged between 18-80 years old.
Patients with ACS (UA/NSTEMI/STEMI) undergoing PCI.
Patients will be treated with DAPT (P2Y12 inhibitors+aspirin) for at least 3 months.
Patients are willing to provide a DNA sample (via blood draw) for CYP2C19 genotyping.
Disqualifiers
Patient with known CYP2C19 genotype before randomization.
Anticipated discontinuation of clopidogrel or ticagrelor within the 12-month follow-up period.
Planned surgery within 90 days.
Requiring oral anticoagulation therapy (eg, atrial fibrillation, deep vein thrombosis, pulmonary thromboembolism)
Trial design
Treatments tested in this trial
- CYP2C19 Genotype Guided DAPT
- Conventional DAPT
Treatment groups
1,200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov